Workflow
达安基因(002030) - 2023 Q1 - 季度财报
002030DAJY(002030)2023-04-28 16:00

Financial Performance - The company's revenue for Q1 2023 was ¥341,038,087.62, a decrease of 89.86% compared to ¥3,362,176,107.47 in the same period last year[6] - Net profit attributable to shareholders was ¥36,561,352.66, down 97.82% from ¥1,679,951,294.17 year-on-year[6] - The net profit after deducting non-recurring gains and losses was ¥18,291,516.52, reflecting a decline of 98.90% compared to ¥1,667,947,149.90 in the previous year[6] - Basic and diluted earnings per share were both ¥0.0261, down 97.82% from ¥1.1970 year-on-year[6] - The weighted average return on equity was 0.32%, a significant drop from 20.51% in the previous year[6] - Operating revenue decreased by 89.86% to ¥341,038,087.62 due to reduced demand for COVID-related testing products[17] - Net profit attributable to shareholders of the parent company fell by 97.82% to ¥36,561,352.66, reflecting the decline in operating revenue[17] - Basic earnings per share decreased by 97.82% to ¥0.0261, driven by the drop in operating income[17] - The net profit for the first quarter of 2023 is CNY 37,777,912.70, compared to CNY 1,690,221,238.84 in the previous year, indicating a significant decrease[43] - The total profit before tax is CNY 49,925,181.66, significantly lower than CNY 1,992,346,057.56 from the previous year[43] - The total comprehensive income for the current period is CNY 37,408,320.51, down from CNY 1,690,303,553.03 in the previous year[43] Cash Flow and Expenses - The net cash flow from operating activities was -¥360,633,771.25, a decrease of 142.96% from ¥839,383,630.81 in the same period last year[6] - Cash flow from operating activities showed a net outflow of ¥360,633,771.25, a decrease of 142.96% compared to the previous year[17] - The cash inflow from operating activities decreased to CNY 1,241,998,318.39 from CNY 2,971,835,343.11 year-over-year[46] - The total cash outflow from investment activities was 749,122,188.26, down from 1,019,955,951.43, reflecting a reduction of about 26.5%[49] - The net cash flow from investment activities was -109,305,166.72, an improvement from -495,975,057.52 in the previous period, showing a decrease in losses by approximately 78%[49] - The net cash flow from financing activities was -34,624,291.54, compared to -26,494,506.77 in the previous period, indicating a worsening of about 30.5%[52] Assets and Liabilities - The total assets decreased to CNY 13,835,070,979.37 from CNY 14,757,073,817.98, a decline of approximately 6.3%[33] - Total current liabilities decreased to CNY 2,045,069,638.41 from CNY 2,968,742,968.32, a decline of approximately 31%[32] - Non-current liabilities decreased to CNY 136,684,654.18 from CNY 172,422,483.39, a reduction of about 20.7%[37] - The total liabilities decreased significantly, with lease liabilities down by 64.89% to ¥23,657,753.42 due to the return of leased premises[17] - The ending balance of cash and cash equivalents was 2,085,554,682.86, down from 2,481,979,285.72, representing a decrease of approximately 16%[52] Shareholder Information - The total share capital as of the last trading day before disclosure was 1,403,446,032 shares[9] - The company reported a total of 188,626 common shareholders at the end of the reporting period[60] - The largest shareholder, Guangzhou Guangyong Technology Development Co., Ltd., holds 16.63% of the shares, totaling 233,391,995 shares[60] Research and Development - Research and development expenses decreased by 36.22% to ¥76,407,740.73 due to adjustments in the R&D structure[17] - Research and development expenses amount to CNY 76,407,740.73, compared to CNY 119,790,428.09 in the previous year, reflecting a decrease in investment in innovation[43] Other Income and Financial Management - The company reported non-recurring gains of ¥10,844,623.63 from government subsidies related to normal business operations[10] - Financial expenses increased significantly by 325.16% to -¥11,690,616.19, attributed to increased interest income from time deposits[17] - Other income rose by 57.91% to ¥17,467,342.87, reflecting an increase in recognized other income compared to the same period last year[17] - Investment income turned negative at -¥13,106,754.85, primarily due to losses from joint ventures[17] - The company reported a tax expense of CNY 12,147,268.96, compared to CNY 302,124,818.72 in the previous year, indicating a reduction in tax liabilities[43] Future Outlook - The company plans to focus on expanding its market presence and developing new products and technologies in the upcoming quarters[1]